ライフサイエンスコーパス: human papilloma virus

1 and immortalized with the E6 and E7 genes of human papilloma virus.

2 en identified as an important target for the Human Papilloma Virus.

3 no acids 85-115 of the E4 protein of type 75 human papilloma virus.

4 ent pathway since ME180 is infected with the human papilloma virus.

5 c strategies against oncogenesis mediated by human papilloma virus.

6 an increasing percentage are associated with human papilloma virus.

7 ions, such as the vaccines for influenza and human papilloma virus.

8 al virus, adeno-associated virus type 2, and human papilloma virus.

9 erminal end of the E6 protein from high-risk Human Papilloma Virus.

10 ely due to elimination of foreskin harboring human papilloma virus.

11 vaccines are available against rotavirus and human papilloma virus.

12 -1, hepatitis B virus, hepatitis C virus and human papilloma virus.

13 lloma virus 16 copies/cell, and SiHa, 1 to 2 human papilloma virus 16 copies/cell) and two negative c

14 known viral gene content (CaSki, 200 to 600 human papilloma virus 16 copies/cell, and SiHa, 1 to 2 h

15 HPECs are immortalized using human papilloma virus 16 E6 and/or E7 as molecular tools

16 enes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen.

17 Expression of the human papilloma virus 16 E7 protein (which inactivates a

18 cell-cycle checkpoints (for example, E7 from human papilloma virus 16, and cyclin D1), deregulate Myc

19 Human papilloma virus-16 (HPV-16) associated oropharynge

20 (rLm) strains were produced that secrete the human papilloma virus-16 (HPV-16) E7 protein expressed i

21 sduced with a retroviral vector encoding the human papilloma virus 18 E6 gene, which inactivates endo

22 on of T-cell chemotaxis in a model of stable human papilloma virus-18 infection.

23 Two capsid virus-like particles, human papilloma virus (55 nm, approximately 20,000 kDa)

24 ive effect of Prdx6, which was observed in a human papilloma virus 8-induced and a chemically induced

25 Infection of influenza or human papilloma virus 9-mer peptide-pulsed DCs from diff

26 to evaluate temporal trends and the role of human papilloma virus and to determine the academic trai

27 Two therapeutic vaccine candidates against human papilloma viruses and melanoma have been developed

28 oradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infectio

29 High-risk human papilloma viruses are known to be associated with

30 ith head and neck squamous cell cancer, both human papilloma virus-associated and human papilloma vir

31 are of renewed importance in the context of human papilloma virus-associated disease, in which young

32 enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal SCC, we h

33 enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal squamous

34 3G and induces G-to-A or C-to-T mutations in human papilloma virus cervical cell lines and genital wa

35 's and NBF solutions were also evaluated for human papilloma virus content using DNA ISH.

36 sociated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has

37 A decamer d(GACCGCGGTC), containing half the human papilloma virus E2 binding site, has been solved f

38 vate transcription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-exp

39 induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent act

40 Inactivation of p53, by the human papilloma virus E6 oncoprotein, does not prevent P

41 erpart, ubiquitinates p53 in the presence of human papilloma virus E6 protein, while Nedd-4 does not.

42 and can be abrogated by the co-expression of human papilloma virus E6 protein.

43 Elimination of p53 by expression of human papilloma virus E6 resulted in an inability to dow

44 The human papilloma virus E6-associated protein (E6AP) funct

45 wth inhibition in melanoma, colon cancer and human papilloma virus-E6/E7 tumour models.

46 frequently inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer.

47 apamycin affects the antitumor efficacy of a human papilloma virus E7 peptide vaccine (CyaA-E7) capab

48 eter for the growthpromoting activity of the human papilloma virus E7 protein.

49 ormed mouse embryonic fibroblasts but not in human papilloma virus-E7 expressing fibroblasts.

50 tes, the only cell type directly infected by human papilloma virus, express functional gammac and its

51 Human papilloma virus has shown differential levels of p

52 y to test women for the causative agent, the human papilloma virus, has emerged as a potential screen

53 Vaccines against rotavirus and human papilloma virus have entered clinical use.

54 ficiency virus, human T cell leukemia virus, human papilloma virus, hepatitis B and C viruses, herpes

55 like the other group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobact

56 like the other Group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobact

57 Risk factors, including human papilloma virus, HIV, and the practice of circumci

58 ic viral diseases such as hepatitis B virus, human papilloma virus, HIV, or chronic hepatitis C.

59 cer have focused on its association with the human papilloma virus; however, there have also been sev

60 ating a peptide from the clinically-relevant human papilloma virus (HPV) 16 E7 oncoprotein induces cy

61 Identifying human papilloma virus (HPV) and human immunodeficiency v

62 n patients whose lesions tested positive for human papilloma virus (HPV) and/or who endorsed a histor

63 High-risk types of human papilloma virus (HPV) are increasingly associated

64 Human papilloma virus (HPV) causes focal infections of e

65 treated with vemurafenib for the presence of human papilloma virus (HPV) DNA and identified 13% to be

66 The prevalence of human papilloma virus (HPV) DNA in different histologica

67 We assayed for the presence of human papilloma virus (HPV) DNA in serum and/or peripher

68 The E6 and E7 oncoproteins of human papilloma virus (HPV) drive the majority of genita

69 mor suppressor pathways are disrupted by the human papilloma virus (HPV) E6 and E7 oncoproteins, beca

70 inocytes and identified protein partners for human papilloma virus (HPV) E6 proteins.

71 Loss of p16(INK4A) or the presence of human papilloma virus (HPV) E6/E7 oncogene products not

72 Recently, the human papilloma virus (HPV) has been implicated in the r

73 n cervical cancer has elucidated the role of human papilloma virus (HPV) in the pathogenesis of cervi

74 carcinomas (OPSCC) that are associated with human papilloma virus (HPV) infection carry a more favor

75 ve implicated estrogenic exposure as well as human papilloma virus (HPV) infection in cervical carcin

76 s was confirmed by a study on the effects of human papilloma virus (HPV) infection to the EC's respon

77 In a longitudinal study of human papilloma virus (HPV) infection, female adolescent

78 maller case-control datasets (samples either Human Papilloma Virus (HPV) positive or negative).

79 In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likel

80 E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for t

81 Specific human papilloma virus (HPV) types appear to be necessary

82 ssociated with approximately 13 carcinogenic human papilloma virus (HPV) types in a broader group tha

83 Despite preventive human papilloma virus (HPV) vaccination efforts, cervica

84 es discussed include influenza, hepatitis B, human papilloma virus (HPV), human T-cell lymphotrophic

85 itis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic v

86 e than 99% of cervical cancers are caused by human papilloma virus (HPV), measurement of HPV (HPV tes

87 DNA of human papilloma virus (HPV), the major etiological agent

88 Human papilloma virus (HPV)-16 DNA was hybridized to pro

89 We have shown that the human papilloma virus (HPV)-16 E7 gene is sufficient to

90 or Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associa

91 arison of normal oral epithelial cells and a human papilloma virus (HPV)-immortalized oral epithelial

92 In the TC-1 mouse allograft model of human papilloma virus (HPV)-induced cancer, a single adm

93 Human papilloma virus (HPV)-like particles (VLPs) have b

94 ma of the vulva is diverse and includes both human papilloma virus (HPV)-positive and HPV-negative pa

95 Purpose The incidence of human papilloma virus (HPV)-positive oropharyngeal cance

96 were particularly higher among patients with human papilloma virus (HPV)-positive tumors.

97 n HIV-positive patients followed closely for human papilloma virus (HPV)-related anal neoplasia after

98 ent tumor induction by pathogenic strains of human papilloma virus (HPV).

99 osure to tobacco, alcohol and infection with human papilloma virus (HPV).

100 cle and transcription of oncogenes, HIV, and human papilloma virus (HPV).

101 ease with solar radiation exposure, HIV, and human papilloma virus (HPV).

102 c cell lines in which p53 was inactivated by human papilloma virus (HPV)16E6 protein or by a dominant

103 prevention and screening recommendations for human papilloma virus (HPV); and appropriate testing for

104 protein (LAMP-1) to the cytoplasmic/nuclear human papilloma virus (HPV-16) E7 antigen, creating a ch

105 ble of controlling tumors induced by type 16 human papilloma virus (HPV-16).

106 Over the past 20 years, high-risk human papilloma-virus (HPV) infection has been establish

107 their association with high-risk subtypes of human papilloma virus (HPV16 and HPV18).

108 The impact of human papilloma virus (HPV16) E7 proteins and retinoblas

109 High-risk human papilloma viruses (HPVs) have been recognized as i

110 etiological role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is

111 linked to infection with high-risk types of human papilloma viruses (HPVs).

112 ers et al. (2014) demonstrate that high-risk human papilloma viruses (hrHPVs) attenuate the magnitude

113 anced cytokine expression and the absence of human papilloma virus in aggressive tumors.

114 uced cytokine expression and the presence of human papilloma virus in chemoradiation-sensitive basalo

115 RKO cells transfected with the E6 protein of human papilloma virus (inactivating p53).

116 elial tumours induced by 'high-risk' mucosal human papilloma viruses, including human cervical carcin

117 ntial DNA methylation changes in relation to human papilloma virus infection and age.

118 and is typically associated with anogenital human papilloma virus infection.

119 Cervical cancer is associated with human papilloma virus infection.

120 order comprising susceptibility to cutaneous human papilloma virus infections and associated nonmelan

121 neages, a long-term risk of severe cutaneous human papilloma virus infections persists, possibly rela

122 Sexual transmission of human papilloma virus is a leading risk factor for cervi

123 , such that loss of p53 through mutation, or human papilloma virus-mediated inhibition, prevents recr

124 r, both human papilloma virus-associated and human papilloma virus-negative tumors.

125 The human papilloma virus oncogene 16E6 induces telomerase a

126 utations in the pocket and by binding of the human papilloma virus oncoprotein E7.

127 ge T antigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the

128 other organs or any history of herpes virus, human papilloma virus, or human immunodeficiency virus i

129 here up-regulated DEK protein levels in both human papilloma virus-positive hyperplastic murine skin

130 Human papilloma virus presence does not seem to be requi

131 ical, mental, and sexual health (including a human papilloma virus programme), an investment of US$4.

132 Inactivation of pocket proteins with human papilloma virus protein E7 partially, but not comp

133 er, although a recent study also showed that human papilloma virus-reactive T cells can induce comple

134 Funding for human papilloma virus-related projects gradually rose, f

135 activity against herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV)

136 with the E6 and E7 transforming proteins of human papilloma virus serotype 16 was necessary to estab

137 ch as human immunodeficiency virus (HIV) and human papilloma virus; several cancers, including follic

138 Human papilloma virus status was not found to be associa

139 Despite infection with high-risk human papilloma virus subtypes, which is a major etiolog

140 These guidelines incorporate human papilloma virus testing based on a multicenter tri

141 the appropriate methods of incorporation of human papilloma virus testing into the screening protoco

142 eceptor, and MIS inhibits the growth of both human papilloma virus-transformed and non-human papillom

143 th human papilloma virus-transformed and non-human papilloma virus-transformed cervical cell lines, w

144 of a ternary complex comprising full-length human papilloma virus type 16 (HPV-16) E6, the LxxLL mot

145 that TR2 is able to induce the expression of human papilloma virus type 16 (HPV-16) genes via binding

146 es and is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulato

147 E7 is the main transforming protein of human papilloma virus type 16 (HPV16) which is implicate

148 Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative

149 al parental cultures with viral oncoproteins human papilloma virus type 16 E6/E7 with and without hTE

150 , E7 (which binds pRB), or both E6 and E7 of human papilloma virus type 16.

151 romosome 8q24.21 at which integration of the human papilloma virus type 18 (HPV-18) genome occurred a

152 , v-src, mutant type 5 adenovirus (Ad5), and human papilloma virus type 18.

153 A peptide from human papilloma virus type 40 (HPV 40) containing VHFFR,

154 the linkage of CRT to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, for the devel

155 s enhanced adjuvant activity, such as in the human papilloma virus vaccine Cervarix(R).

156 ation or the expression of the E6 protein of human papilloma virus, were treated with exogenous ceram